| 1 | Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. (Schöffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI) Eur J Cancer 2017 Nov;86:296-304 59 Citations |
| 1 | Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohort. (Dungan K, Craven TE, Soe K, Wright JT Jr, Basile J, Haley WE, Kressin NR, Rani U, Tamariz L, Whittle J, Wiggers A, Osei K) Diabetes Obes Metab 2018 Mar;20(3):629-637 5 Citations |
| 1 | Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. (Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M) Cancer 2014 Mar 01;120(5):692-701 92 Citations |
| 1 | Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial. (Bulger EM, May S, Kerby JD, Emerson S, Stiell IG, Schreiber MA, Brasel KJ, Tisherman SA, Coimbra R, Rizoli S, Minei JP, Hata JS, Sopko G, Evans DC, Hoyt DB, ROC investigators) Ann Surg 2011 Mar;253(3):431-41 236 Citations |
